Redefining Cancer Care –
Tailor-made therapies to improve each patient’s quality of life.
At YGION, we envision a future where each cancer patient receives a bespoke therapy designed to fit their unique disease profile.
This approach maximizes effectiveness and minimizes side effects, paving the way for enhanced patient outcomes and better quality of life.
Target. Activate. Eradicate.
Eliminating cancer with tailor-made precision
By triggering a customized, tumor-specific immune response and harnessing the power of each patient’s own immune system, we aim to empower it to identify and destroy tumor cells.
NEWS
YGION Biomedical attends leading Partnering Conferences
CBO, Dr Sophie Zettl will be attending key partnering and investment conferences this Spring to discuss collaboration and investment opportunities at YGION Biomedical. On March 23-26th 2026, YGION will be attending BioEurope...
8th International Neoantigen Summit
YGION Biomedical’s CSO, Dr Anna-Dorothea Gorki is attending the 8th International Neoantigen Summit on June 24-26, in Amsterdam, Netherlands. This conference brings together the global neoantigen community to address key challenges in the...
YGION Biomedical at Partnering Conferences
The YGION Biomedical team will be attending a number of international conferences this Autumn. To explore partnerships in Asia and beyond, the team will be joining the Austrian delegation of the...
7th International Neoantigen Summit
YGION Biomedical’s team is attending the 7th International Neoantigen Summit from April 29 – May 1, in Amsterdam, Netherlands. This meeting unites the international neoantigen community to overcome neoantigen identification, prediction, and...
YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A financing round of €15 million from an Austrian private trust. The...
YGION Biomedical Awarded Grant from the Austrian Research Promotion Agency to develop Individualized Cancer Immunotherapies
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer immunotherapies, today announces further fundraising news with the award of a significant Life Sciences grant from the...
